Sugi Predict

Sugi Predict / Compounds / SCHEMBL1883225

SCHEMBL1883225

SCHEMBL1883225

CCOC(=O)c1cc2c(Cl)c(F)ccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.58
▸ ALDH1A1 P00352 5/20 0.53
▸ HPGD P15428 4/20 0.53
▸ KDM4E B2RXH2 4/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ NPC1 O15118 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ HRH3 Q9Y5N1 1/20 0.50
▸ MMP13 P45452 4/20 0.49
▸ MMP2 P08253 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ GAA P10253 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ GLA P06280 1/20 0.49
▸ ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30193757 1.00 ALOX15 (0.58) ALOX15ALDH1A1HPGDKDM4ERAB9A
SCHEMBL30525427 0.86 ALOX15 (0.57) ALOX15ALDH1A1HPGDKDM4ERAB9A
SCHEMBL699665 0.86 ALOX15 (0.57) ALOX15ALDH1A1HPGDKDM4ERAB9A
SCHEMBL19332451 0.86 ALOX15 (0.57) ALOX15ALDH1A1HPGDKDM4ERAB9A
SCHEMBL5622542 0.86 KDM4E (0.56) ALOX15ALDH1A1HPGDKDM4ERAB9A
SCHEMBL4404148 0.86 KDM4E (0.56) ALOX15ALDH1A1HPGDKDM4ERAB9A
SCHEMBL31416403 0.85 ALOX15 (0.52) ALOX15ALDH1A1HPGDKDM4ERAB9A
SCHEMBL30310454 0.85 DAO (0.52) ALDH1A1HPGDKDM4EDAOALOX5
SCHEMBL19332317 0.85 DAO (0.52) ALDH1A1HPGDKDM4EDAOALOX5
SCHEMBL13593176 0.84 DAO (0.55) ALOX15ALDH1A1KDM4EHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747234-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 — — EP disclosed
WO-2025017103-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS MUNA THERAPEUTICS APS (DK) 2025-01-23 — — WO disclosed
EP-3884939-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
EP-3884939-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 — — US disclosed
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2023-04-25 — — US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 — — US disclosed
US-20070293668-A1 Phenylindoles for the treatment of HIV LACOLLA PAULO 2007-12-20 — — US disclosed
EP-1863798-A1 INDOLE DERIVATIVES Mitsubishi Tanabe Pharma Corporation (JP) 2007-12-12 — — EP disclosed
WO-2006080577-A1 INDOLE DERIVATIVES TANABE SEIYAKU CO., LTD. (JP) 2006-08-03 — — WO disclosed
EP-1390029-A4 PHENYLINDOLES FOR THE TREATMENT OF HIV IDENIX CAYMAN LTD (KY) 2005-11-30 — — EP disclosed
US-20040180888-A1 Phenylindoles for the treatment of HIV IDENIX PHARMACEUTICALS INC. 2004-09-16 — — US disclosed
US-6710068-B2 PHENYLSULFONYLINODLES USEFUL FOR THE TREATMENT OF HIV IN HUMANS AND OTHER HOST ANIMALS IDENIX PHARMACEUTICALS, INC. 2004-03-23 — — US disclosed
EP-1390029-A1 PHENYLINDOLES FOR THE TREATMENT OF HIV Idenix (Cayman) Limited (KY) 2004-02-25 — — EP disclosed
US-20020193415-A1 Phenylindoles for the treatment of HIV IDENIX PHARMACEUTICALS INC. 2002-12-19 — — US disclosed
WO-2002083126-A1 PHENYLINDOLES FOR THE TREATMENT OF HIV IDENIX (CAYMAN) LIMITED (KY) 2002-10-24 — — WO disclosed
US-5494928-A FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS HOFFMANN-LA ROCHE INC. (US) 1996-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293668-A1 Phenylindoles for the treatment of HIV DUT, NQO1, ENTPD5 ALOX15 3413/4885ALDH1A1 1178/4885HPGD 265/4885
US-20020193415-A1 Phenylindoles for the treatment of HIV DUT, NQO1, ENTPD5 ALOX15 3413/4885ALDH1A1 1178/4885HPGD 265/4885
US-11634412-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD ALOX15 3424/4885ALDH1A1 222/4885HPGD 97/4885
US-20040180888-A1 Phenylindoles for the treatment of HIV DUT, NQO1, ENTPD5 ALOX15 3413/4885ALDH1A1 1178/4885HPGD 265/4885
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD ALOX15 3424/4885ALDH1A1 222/4885HPGD 97/4885
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD ALOX15 3424/4885ALDH1A1 222/4885HPGD 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.